Alisa A. Suen

Alisa A. Suen

Auto-generated profile, based on publicly available information

Alisa A. Suen

Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Reproductive Toxicology
Verified
Journal Article
Closed access
SHShuk-Mei Ho
Shuk-Mei Ho
ACAna Cheong
Ana Cheong
MAMargaret A. Adgent
Margaret A. Adgent
JVJennifer Veevers
Jennifer Veevers
ASAlisa A. Suen
Alisa A. Suen
CWCarmen J. Williams
Carmen J. Williams

13 December 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
XBXue Bai
Xue Bai
KLKaitlin C. Lenhart
Kaitlin C. Lenhart
KBKim E. Bird
Kim E. Bird
ASAlisa A. Suen
Alisa A. Suen
MRMauricio Rojas
Mauricio Rojas
JTJoan M. Taylor
Joan M. Taylor
Although hypertension is a worldwide health issue, an incomplete understanding of its aetiology has hindered our ability to treat this complex disease. Here we identify arhgap42 (also known as GRAF3) as a Rho-specific GAP expressed specifically in smooth muscle cells (SMCs) in mice and humans. We show that GRAF3-deficient mice exhibit significant hypertension and increased pressor responses to angiotensin II and endothelin-1; these effects are prevented by treatment with the Rho-kinase inhibitor, Y27632. RhoA activity and myosin light chain phosphorylation are elevated in GRAF3-depleted SMCs in vitro and in vivo, and isolated vessel segments from GRAF3-deficient mice show increased contractility. Taken together, our data indicate that GRAF3-mediated inhibition of RhoA activity in vascular SMCs is necessary for maintaining normal blood pressure homoeostasis. Moreover, these findings provide a potential mechanism for a hypertensive locus recently identified within arhgap42 and provide a foundation for the future development of innovative hypertension therapies.

1 September 2016 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAlisa A. Suen
Alisa A. Suen
WJWendy N. Jefferson
Wendy N. Jefferson
CWCharles E. Wood
Charles E. Wood
EPElizabeth Padilla-Banks
Elizabeth Padilla-Banks
VBVictoria L. Bae-Jump
Victoria L. Bae-Jump
CWCarmen J. Williams
Carmen J. Williams
The oncofetal protein sine oculis-related homeobox 1 (SIX1) is a developmental transcription factor associated with carcinogenesis in several human cancer types but has not been investigated in human endometrial cancer. In a model of hormonal carcinogenesis, mice neonatally exposed to the soy phytoestrogen genistein (GEN) or the synthetic estrogen diethylstilbestrol (DES) develop endometrial cancer as adults. Previously, we demonstrated that SIX1 becomes aberrantly expressed in the uteri of these mice. Here, we used this mouse model to investigate the role of SIX1 expression in endometrial carcinoma development and used human tissue microarrays to explore the utility of SIX1 as a biomarker in human endometrial cancer. In mice neonatally exposed to GEN or DES, the Six1 transcript level increased dramatically over time in uteri at 6, 12, and 18 months of age and was associated with development of endometrial carcinoma. SIX1 protein localized within abnormal basal cells and all atypical hyperplastic and neoplastic lesions. These findings indicate that developmental estrogenic chemical exposure induces persistent endometrial SIX1 expression that is strongly associated with abnormal cell differentiation and cancer development. In human endometrial tissue specimens, SIX1 was not present in normal endometrium but was expressed in a subset of endometrial cancers in patients who were also more likely to have late-stage disease. These findings identify SIX1 as a disease biomarker in a model of hormonal carcinogenesis and suggest that SIX1 plays a role in endometrial cancer development in both mice and women. Implications: The SIX1 oncoprotein is aberrantly expressed in the endometrium following developmental exposure to estrogenic chemicals, correlates with uterine cancer, and is a biomarker in human endometrial cancers. Mol Cancer Res; 14(9); 849–58. ©2016 AACR.

18 November 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ASAlisa A. Suen
Alisa A. Suen
AKAnna C. Kenan
Anna C. Kenan
CWCarmen J. Williams
Carmen J. Williams

10 April 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
WJWendy N Jefferson
Wendy N Jefferson
HKH Karimi Kinyamu
H Karimi Kinyamu
TWTianyuan Wang
Tianyuan Wang
AMAdam X Miranda
Adam X Miranda
EPElizabeth Padilla-Banks
Elizabeth Padilla-Banks
CWCarmen J Williams
Carmen J Williams
Little is known regarding how steroid hormone exposures impact the epigenetic landscape in a living organism. Here, we took a global approach to understanding how exposure to the estrogenic chemical, diethylstilbestrol (DES), affects the neonatal mouse uterine epigenome. Integration of RNA- and ChIP-sequencing data demonstrated that ∼80% of DES-altered genes had higher H3K4me1/H3K27ac signal in close proximity. Active enhancers, of which ∼3% were super-enhancers, had a high density of estrogen receptor alpha (ERα) binding sites and were correlated with alterations in nearby gene expression. Conditional uterine deletion of ERα, but not the pioneer transcription factors FOXA2 or FOXO1, prevented the majority of DES-mediated changes in gene expression and H3K27ac signal at target enhancers. An ERα dependent super-enhancer was located at the Padi gene locus and a topological connection to the Padi1 TSS was documented using 3C-PCR. Chromosome looping at this site was independent of ERα and DES exposure, indicating that the interaction is established prior to ligand signaling. However, enrichment of H3K27ac and transcriptional activation at this locus was both DES and ERα-dependent. These data suggest that DES alters uterine development and consequently adult reproductive function by modifying the enhancer landscape at ERα binding sites near estrogen-regulated genes.

1 April 2013 in Journal of Molecular Biology
Verified
Journal Article
Closed access
TATrevor A. Addington
Trevor A. Addington
RMRobert W. Mertz
Robert W. Mertz
JSJustin B. Siegel
Justin B. Siegel
JTJames M. Thompson
James M. Thompson
AFAndrew Fisher
Andrew Fisher
MTMichael D. Toney
Michael D. Toney